Welcome to our dedicated page for ALLURION TECHNOLOGIES SEC filings (Ticker: ALUR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Allurion Technologies, Inc. (NYSE: ALUR) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents offer detailed information about Allurion’s medical device business focused on metabolically healthy weight loss, its Allurion Program, and the Allurion Smart Capsule, which the company describes as a swallowable, Procedureless™ gastric balloon for weight loss and an investigational device in the United States.
Through periodic reports and current reports on Form 8-K, Allurion outlines financial results, capital structure changes, and governance matters. Filings referenced in recent disclosures include notifications of late filing on Form 12b-25, restatements related to accounting for a revenue interest financing agreement and convertible senior secured notes, and descriptions of material weaknesses in internal control over financial reporting. Investors can review these filings to understand how non-cash accounting adjustments affect items such as Other Comprehensive Income (Loss) and Other Income (Expense), as well as the company’s commentary that these corrections are not expected to impact revenue, gross margin, operating expenses, or cash.
Allurion’s SEC filings also describe capital markets and financing transactions, such as a private placement of common stock and accompanying warrants, and an exchange agreement to convert outstanding debt and obligations under revenue interest financing agreements into shares of Series B convertible preferred stock, subject to stockholder approval and exchange listing requirements. Definitive proxy materials provide further detail on proposals for stockholders, including amendments to stock plans, option repricing, preferred share and warrant share issuances, and a potential reverse stock split within an approved ratio range.
On Stock Titan, these filings are supplemented with AI-powered summaries that explain the key points of complex documents like 10-Ks, 10-Qs, 8-Ks, and proxy statements in plain language. Users can quickly see the main themes in Allurion’s disclosures on regulatory progress for the Allurion Smart Capsule, financial performance, risk factors, and governance decisions, while still having access to the full original SEC documents for deeper analysis.
Allurion Technologies (ALUR) amended its quarterly report to reflect a prior restatement and to disclose post-business-combination corporate and financing activity. The company completed a business combination with Compute Health and applied a reverse stock split, which changed warrant and share conversion ratios. It disclosed multiple equity and warrant offerings closed in January and February 2025 that raised net proceeds of $5.8 million and $3.9 million, respectively, and additional private placements raising $2.5 million and $1.3 million. The company described amendments to a revenue interest financing agreement that increased revenue-interest rates and related derivative accounting, conversions and debt modifications, and recorded related liabilities and remeasurements. Allurion operates in ~50 countries, provides the Allurion Program and App for remote patient monitoring, and disclosed remediation steps for previously identified internal control weaknesses and an NYSE cure plan.
Allurion Technologies (ALUR) amended its annual report describing strategic, operational and financial risks tied to its post‑merger transition and commercialization of the Allurion Balloon. The company completed a Business Combination with Compute Health and various financings including a July 1, 2024 public offering that raised net proceeds of $15.2 million and multiple private placements. Allurion sells the Allurion Balloon and an AI‑powered Virtual Care Suite (VCS) in over 40 countries but the Balloon is not approved for commercial sale in the U.S. The filing discloses a restatement of prior financial statements, material weaknesses in internal controls, significant debt and revenue‑interest financing with RTW that carries contingent payment rates and covenants. The company states it has incurred losses and expects losses to continue while FDA approval, regulatory compliance, NYSE cure planning, supply, and reimbursement risks remain material.
Allurion Technologies, Inc. filed a Form 12b-25 notifying the SEC that its Form 10-Q for the quarter ended June 30, 2025 could not be filed on time. The notice identifies Brendan M. Gibbons, Chief Legal Officer as the contact and confirms that other periodic reports required over the prior 12 months have been filed. The company indicates it anticipates a significant change in results of operations for the period and includes customary forward-looking risk disclosures about potential adjustments to prior statements, regulatory or legal actions, possible delisting, and timing uncertainties related to completing and filing the 10-Q.
Allurion Technologies, Inc. disclosed accounting issues requiring correction and potential amendments to prior SEC reports, noting the company does not expect the corrections to affect reported revenue, gross margin, operating expenses, or cash. The filing flags risks including additional adjustments to prior statements, a delayed Q2 Quarterly Report for the period ended June 30, 2025, possible SEC or regulatory investigations, potential NYSE delisting, and shareholder litigation. The statement frames these as forward-looking risks while the company completes its evaluation.
Allurion Technologies said it issued a press release covering results for the three and six months ended June 30, 2025 and disclosed a potential accounting error. The company identified a likely miscalculation in non-cash items—Other Comprehensive Income (Loss) and Other Income (Expense)—related to the fair value of its Revenue Interest Financing Agreement (RIFA) and convertible notes, and believes correcting those calculations will likely require restating prior-period financial statements. The company stated these adjustments are non-cash and are not expected to affect revenue, gross margin, operating expenses, or cash. The press release is furnished as Exhibit 99.1.